{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:14:12Z","timestamp":1793229252472,"version":"4.5.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/jcp.0b013e3181bf613e","type":"journal-article","created":{"date-parts":[[2009,11,7]],"date-time":"2009-11-07T03:15:39Z","timestamp":1257563739000},"page":"529-536","source":"Crossref","is-referenced-by-count":21,"title":["Improved Body Weight and Metabolic Outcomes in Overweight or Obese Psychiatric Patients Switched to Amisulpride From Other Atypical Antipsychotics"],"prefix":"10.1097","volume":"29","author":[{"given":"Chao-Cheng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Mei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chieh","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ching","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Yeu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiow-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan S.F.","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jay","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.","volume":"159","author":"Bilder","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.","volume":"57","author":"Purdon","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.","volume":"162","author":"Schooler","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001504-200503000-00011","article-title":"Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics.","volume":"18","author":"Rettenbacher","year":"2005","journal-title":"Curr Opin Psychiatry"},{"issue":"suppl 6","key":"R7-3-20210128","first-page":"14","article-title":"Reducing the burden of side effects during long-term antipsychotic therapy: the role of \"switching\" medications.","volume":"68","author":"Weiden","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0033-3506(97)00089-9","article-title":"Somatic morbidity in schizophrenia-a case control study.","volume":"111","author":"Dalmau","year":"1997","journal-title":"Public Health"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.173.1.11","article-title":"Excess mortality of mental disorder.","volume":"173","author":"Harris","year":"1998","journal-title":"Br J Psychiatry"},{"issue":"suppl 7","key":"R10-3-20210128","first-page":"32","article-title":"The clinical implications of weight gain in schizophrenia.","volume":"62","author":"Kurzthaler","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"suppl 7","key":"R11-3-20210128","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature.","volume":"62","author":"Allison","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia.","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatr Serv"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004850-200207000-00001","article-title":"Options for pharmacological management of obesity in patients treated with atypical antipsychotics.","volume":"17","author":"Werneke","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance.","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.","volume":"83","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4088\/JCP.v68n1202","article-title":"Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.","volume":"68","author":"Bai","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"suppl 4","key":"R18-3-20210128","first-page":"34","article-title":"Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.","volume":"68","author":"Weiden","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.","volume":"23","author":"Weiden","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pnpbp.2006.10.002","article-title":"Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.","volume":"31","author":"Montes","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity.","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2007-1014494","article-title":"Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study.","volume":"23","author":"Delcker","year":"1990","journal-title":"Pharmacopsychiatry"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002130050614","article-title":"Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology-a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-\/D2-like antagonist. The Amisulpride Study Group.","volume":"137","author":"Wetzel","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050361","article-title":"Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.","volume":"132","author":"Moller","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatr Scand"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.","volume":"15","author":"Colonna","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","article-title":"Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.","volume":"156","author":"Danion","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/ajp.152.1.130","article-title":"Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.","volume":"152","author":"Paillere-Martinot","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.","volume":"170","author":"Loo","year":"1997","journal-title":"Br J Psychiatry"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1192\/bjp.166.1.68","article-title":"Treatment of negative symptoms in schizophrenia with amisulpride.","volume":"166","author":"Boyer","year":"1995","journal-title":"Br J Psychiatry"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1192\/bjp.171.6.564","article-title":"One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.","volume":"171","author":"Speller","year":"1997","journal-title":"Br J Psychiatry"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","article-title":"Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.","volume":"88","author":"Peuskens","year":"1999","journal-title":"Psychiatry Res"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0893-133X(02)00375-5","article-title":"Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.","volume":"27","author":"Sechter","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1185\/030079902125001128","article-title":"A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.","volume":"18","author":"Martin","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-200403000-00002","article-title":"A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.","volume":"19","author":"Mortimer","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00213-003-1721-6","article-title":"Amisulpride is an \"atypical\" antipsychotic associated with low weight gain.","volume":"173","author":"Leucht","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0006-3223(97)00488-5","article-title":"Clozapine and body mass change.","volume":"43","author":"Frankenburg","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s001250051215","article-title":"Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes.","volume":"42","author":"Hermans","year":"1999","journal-title":"Diabetologia"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2002-20524","article-title":"Simplified measurement of insulin sensitivity with the minimal model procedure in type 2 diabetic patients without measurement of insulinemia.","volume":"34","author":"Perez-Martin","year":"2002","journal-title":"Horm Metab Res"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation.","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1176\/ajp.134.7.759","article-title":"Clinical research techniques in tardive dyskinesia.","volume":"134","author":"Fann","year":"1977","journal-title":"Am J Psychiatry"},{"key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/15622970009150593","article-title":"State of the art of drug treatment of schizophrenia and the future position of the novel\/atypical antipsychotics.","volume":"1","author":"Moller","year":"2000","journal-title":"World J Biol Psychiatry"},{"key":"R49-3-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/YIC.0b013e3280148c19","article-title":"Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.","volume":"22","author":"Linden","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.yic.0000224786.75664.3b","article-title":"Early changes of plasma lipids during treatment with atypical antipsychotics.","volume":"21","author":"Rettenbacher","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R51-3-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R52-3-20210128","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R53-3-20210128","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM199805213382106","article-title":"The treatment of unrelated disorders in patients with chronic medical diseases.","volume":"338","author":"Redelmeier","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R54-3-20210128","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"R55-3-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/YIC.0b013e3280148c29","article-title":"Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.","volume":"22","author":"Peuskens","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"R56-3-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0269881106069467","article-title":"Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.","volume":"21","author":"Rettenbacher","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R57-3-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.bp.106.031716","article-title":"Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.","volume":"191","author":"Mackin","year":"2007","journal-title":"Br J Psychiatry"},{"key":"R58-3-20210128","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"R59-3-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","article-title":"Amisulpride-induced hyperprolactinemia is reversible following discontinuation.","volume":"31","author":"Paparrigopoulos","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R60-3-20210128","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ps.2007.58.4.544","article-title":"Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program.","volume":"58","author":"Wu","year":"2007","journal-title":"Psychiatr Serv"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200912000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T22:51:58Z","timestamp":1739400718000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200912000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181bf613e","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}